Abstract
Pre-exposure oral prophylaxis with antiviral drugs is a potential method for preventing transmission of human immunodeficiency virus type 1 (HIV-1). We show that oral delivery of CMPD167, a small molecule that binds to the CCR5 coreceptor, for 10–14 d can protect a substantial proportion of macaques from vaginal infection with a CCR5-using virus (SHIV-162P3). The macaques that became infected despite receiving CMPD167 had reduced plasma viremia levels during the earliest stages of infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Youle, M. & Wainberg, M.A. AIDS 17, 937–938 (2003).
Shattock, R.J. & Moore, J.P. Nat. Rev. Microbiol. 1, 25–34 (2003).
AIDS Vaccine Advocacy Coalition. Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PREP” trials. A special publication of the AIDS Vaccine Advocacy Coalition (AVAC). http://www.avac.org/pdf/tenofovir.pdf. (2005).
Seibert, C. & Sakmar, T.P. Curr. Pharm. Des. 10, 2041–2062 (2004).
Barber, C.G. Curr. Opin. Investig. Drugs 5, 851–861 (2004).
Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T.P. Mol. Pharmacol. 67, 1268–1282 (2005).
Kuhmann, S.E. et al. J. Virol. 78, 2790–2807 (2004).
Veazey, R.S. & Lackner, A.A. Nat. Med. 11, 469–470 (2005).
Veazey, R.S. et al. Nature, published online 30 October 2005 (10.1038/nature04055).
Veazey, R.S. et al. J. Exp. Med. 198, 1551–1562 (2003).
Wolinsky, S.M. et al. Virology 328, 19–29 (2004).
Tsai, C.C. et al. Science 270, 1197–1199 (1995).
Tsai, C.C. et al. J. Virol. 72, 4265–4273 (1998).
Marx, P.A. et al. Nat. Med. 2, 1084–1089 (1996).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Martin S. Springer is an employee of Merck Inc., but this company did not fund the study.
Rights and permissions
About this article
Cite this article
Veazey, R., Springer, M., Marx, P. et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11, 1293–1294 (2005). https://doi.org/10.1038/nm1321
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1321
This article is cited by
-
Oral Administration of the CCR5 Inhibitor, Maraviroc, Blocks HIV Ex Vivo Infection of Langerhans Cells within the Epithelium
Journal of Investigative Dermatology (2013)
-
Clinical use of CCR5 inhibitors in HIV and beyond
Journal of Translational Medicine (2011)
-
Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance
Scientific Reports (2011)
-
Preexposure Prophylaxis for HIV Prevention
Current HIV/AIDS Reports (2011)
-
Pharmacologic Opportunities for HIV Prevention
Clinical Pharmacology & Therapeutics (2010)